RESUMO
BACKGROUND: Despite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been well established. PATIENTS AND METHODS: Fresh tumor and normal adjacent tissue was prospectively collected from 150 patients with localized NSCLC. Tissue was comprehensively characterized by high-dimensional flow cytometry of TILs integrated with immunogenomic data from multiplex immunofluorescence, T-cell receptor sequencing, exome sequencing, RNA sequencing, targeted proteomics, and clinicopathologic features. RESULTS: While neither the magnitude of TIL infiltration nor specific TIL subsets were significantly prognostic alone, the integration of high-dimensional flow cytometry data identified two major immunotypes (IM1 and IM2) that were predictive of recurrence-free survival independent of clinical characteristics. IM2 was associated with poor prognosis and characterized by the presence of proliferating TILs expressing cluster of differentiation 103, programmed cell death protein 1, T-cell immunoglobulin and mucin-domain containing protein 3, and inducible T-cell costimulator. Conversely, IM1 was associated with good prognosis and differentiated by an abundance of CD8+ T cells expressing cytolytic enzymes, CD4+ T cells lacking the expression of inhibitory receptors, and increased levels of B-cell infiltrates and tertiary lymphoid structures. While increased B-cell infiltration was associated with good prognosis, the best prognosis was observed in patients with tumors exhibiting high levels of both B cells and T cells. These findings were validated in patient tumors from The Cancer Genome Atlas. CONCLUSIONS: Our study suggests that although the number of infiltrating T cells is not associated with patient survival, the nature of the infiltrating T cells, resolved in distinct TIL immunotypes, is prognostically relevant in NSCLC and may inform therapeutic approaches to clinical care.
Assuntos
Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Linfócitos T CD8-Positivos , Carcinoma Pulmonar de Células não Pequenas/patologia , Humanos , Neoplasias Pulmonares/patologia , Linfócitos do Interstício Tumoral/patologia , PrognósticoAssuntos
Anticorpos Monoclonais Humanizados , Carcinoma de Célula de Merkel , Neoplasias Hepáticas , Neoplasias Cutâneas , Humanos , Bevacizumab/uso terapêutico , Estudos Prospectivos , Carcinoma de Célula de Merkel/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Protocolos de Quimioterapia Combinada AntineoplásicaRESUMO
Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 years shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using six 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined. The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453. These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.
Assuntos
Neoplasias Encefálicas/genética , Neoplasias da Mama/genética , Cromossomos Humanos Par 18 , Perda de Heterozigosidade , Neoplasias Pulmonares/genética , Alelos , Carcinoma/genética , Carcinoma Pulmonar de Células não Pequenas/genética , Feminino , Frequência do Gene , Marcadores Genéticos , Glioblastoma/genética , Humanos , Masculino , Reação em Cadeia da Polimerase , Polimorfismo Genético , Deleção de SequênciaRESUMO
Aberrations of 13q occur frequently in prostate cancer and this chromosome contains two known tumor suppressor genes, BRCA2 and Rb1. This study analysed 13q LOH, DNA ploidy, BRCA2 mutation and pRb expression in prostate cancers. In total, 13q deletions were found in 18 of 36 tumors but did not correlate with histological grade, stage or DNA ploidy. Two smallest regions of overlapping deletions were defined: one flanked by D13S218 and D13S153; the other flanked by D13S31 and D13S137. BRCA2 was less frequently deleted whereas Rb1 did have a high frequency of deletion. None of the two genes was located in any of these two regions. Furthermore, BRCA2 mutation was not found in the five tumors where deletions had involved the BRCA2 locus. Neither did the Rb1 deletion correlate with absent pRb expression. In addition, tetraploidy was found in 14 out of 25 tumors analysed and correlated with aberrant pRb expression. Our results indicate that 13q deletion is an early non-random event. Tumor suppressor genes other than BRCA2 or Rb1 may be the target of 13q deletions. Aberrant pRb expression may not reflect the two-hit Rb1 inactivation but may be involved in the tetraploidization of prostate cancer cells.
Assuntos
Cromossomos Humanos Par 13/genética , Deleção de Genes , Genes Supressores de Tumor/genética , Neoplasias da Próstata/genética , Idoso , Genes do Retinoblastoma/genética , Humanos , Perda de Heterozigosidade , Masculino , Pessoa de Meia-Idade , Ploidias , Proteína do Retinoblastoma/metabolismoRESUMO
Men who inherit a mutation in the BRCA2 gene carry a 6% risk of developing breast cancer by the age of 70. The proportion of male breast cancers attributable to BRCA mutations has not yet been determined with accuracy. We studied a series of 14 male breast cancer patients, unselected for family history or ethnicity, who were treated at a single regional cancer center in Canada. Family histories were obtained, and the men were tested for germ-line mutations of BRCA1 and BRCA2. Seven of these patients had a significant family history of breast cancer (i.e., at least one first- or second-degree relative with breast cancer diagnosed before age 70). Two of the men carried BRCA2 mutations, but no BRCA1 mutations were found. Both mutation carriers reported a positive family history and a personal history of cancer that preceded their diagnosis of breast cancer. Our results support the recommendation that male breast cancer patients who have a significant family history of breast or ovarian cancer should be offered genetic counseling and testing.
Assuntos
Neoplasias da Mama Masculina/genética , Genes BRCA1 , Genes BRCA2 , Mutação em Linhagem Germinativa/genética , Adulto , Distribuição por Idade , Idade de Início , Idoso , Alcoolismo/complicações , Neoplasias da Mama Masculina/diagnóstico , Neoplasias da Mama Masculina/epidemiologia , Análise Mutacional de DNA/métodos , Aconselhamento Genético , Predisposição Genética para Doença/epidemiologia , Predisposição Genética para Doença/genética , Testes Genéticos/métodos , Heterozigoto , Humanos , Masculino , Anamnese , Pessoa de Meia-Idade , Ontário/epidemiologia , Linhagem , Prevalência , Sistema de Registros , Fatores de RiscoRESUMO
Families with multiple cases of ovarian cancer have long been observed, and in the past prophylactic oophorectomy has been advocated for women with a history of ovarian cancer in two first-degree relatives. It is now thought that > 90% of familial ovarian cancer is due to inherited mutations in the BRCA1 breast-ovarian cancer susceptibility gene on chromosome 17q. BRCA1 testing is being performed in several academic medical centers on a research basis and is also now commercially available. With the ability to identify inherited mutations in BRCA1, prophylactic oophorectomy and other interventions intended to decrease cancer mortality can be offered specifically to women who carry a mutation, but the optimal strategy for decreasing cancer mortality in BRCA1 families has not yet been determined. To facilitate further clinical and basic research in this field, our group and others have established multidisciplinary hereditary breast-ovarian cancer clinics that offer a wide range of services including BRCA1 testing, genetic counseling, and cancer prevention and treatment.
Assuntos
Genes BRCA1/genética , Mutação , Neoplasias Ovarianas/genética , Cromossomos Humanos Par 17 , Feminino , Testes Genéticos , Humanos , Neoplasias Ovarianas/prevenção & controle , Ovariectomia , LinhagemRESUMO
Linkage analysis in German breast cancer families with early onset of the disease by using six markers on chromosome 17q11-q24 has been carried out. In the region between markers D17S250 and GH, three markers showed positive LOD scores at an estimated distance of zero. Evidence for linkage is greatest for D17S250, with a LOD score of 2.42.